Newswire (Published: Thursday, January 3, 2019, 11:00:00 AM CST, Received: Thursday, January 3, 2019, 11:33:02 AM CST)

Word Count: 554

By a News Reporter-Staff News Editor at Clinical Trials Week -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news reporting originating in Calgary, Canada, by NewsRx journalists, research stated, "Local treatment of metastatic prostate cancer and its impact on future disease course is a controversial topic that needs further assessment. Patients with metastatic hormone-sensitive prostate cancer (HSPC) and prior local treatment had better overall, progression-free, and cancer-specific survivals compared to those without prior local treatment."

The news reporters obtained a quote from the research from the University of Calgary, "The impact of these findings on the treatment paradigms for metastatic HSPC should be thoroughly evaluated. Local treatment of metastatic prostate cancer and its impact on future disease course requires further assessment. We sought to evaluate the impact of prior local treatment to the prostate on the outcomes of hormone-sensitive prostate cancer (HSPC) patients recruited in the CHAARTED study. We performed a retrospective analysis of the prospectively collected data among patients with metastatic HSPC in the CHAARTED study, a phase 3 multicenter study conducted between 2006 and 2014. The CHAARTED study compared androgen deprivation therapy plus docetaxel versus androgen deprivation therapy alone among patients with metastatic HSPC. The main outcomes of the current analysis are overall survival, progression-free survival, prostate cancer-specific survival, and time to castration-resistant disease as assessed by Kaplan-Meier analysis, log-rank testing, and Cox regression models. Kaplan-Meier overall survival estimates were produced according to whether patients underwent prior local treatment and results were stratified by treatment arm. For both treatment arms, patients with prior local treatment had better overall survival (P < .01). Similarly, Kaplan-Meier progression-free survival estimates were produced according to whether patients underwent prior local treatment, and results were stratified by the treatment arm. For both treatment arms, patients with prior local treatment had better progression-free survival (P < .01). In an adjusted Cox multivariate model (adjusted for assigned study treatment arm, age, baseline prostate-specific antigen, and baseline Gleason score, volume of the disease (low risk or high risk) and baseline performance status), patients with prior local treatment had better overall survival (P = .045), progression-free survival (P = .035), and cancer-specific survival (P = .010) compared to those without prior local treatment. Moreover, they had a longer time to development of castration-resistant disease (P = .025). Patients with metastatic HSPC and prior local treatment had better overall, progression-free, and cancer-specific survivals compared to those without prior local treatment."

According to the news reporters, the research concluded: "The impact of these findings on the treatment paradigms for metastatic HSPC should be thoroughly evaluated."

For more information on this research see: Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial. Clinical Genitourinary Cancer, 2018;16(6):466-472. Clinical Genitourinary Cancer can be contacted at: Cig Media Group, Lp, 3500 Maple Avenue, Ste 750, Dallas, TX 75219-3931, USA. (Elsevier - www.elsevier.com; Clinical Genitourinary Cancer - www.journals.elsevier.com/clinical-genitourinary-cancer/)

Our news correspondents report that additional information may be obtained by contacting W.Y. Cheung, University of Calgary, Tom Baker Canc Center, Dept. of Oncol, Calgary, AB T2N 4N2, Canada (see also Oncology - Prostate Cancer).

(Our reports deliver fact-based news of research and discoveries from around the world.)

Places

North America
Canada
United States
Americas
Alberta
Texas
Calgary
Dallas

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Pharmaceutical Development
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process
                  Drug Testing and Approval Process
      Treatments and Therapies
            Medicinal Drugs
                  Drug Testing and Approval Process